老药新用：硒代-L-甲硫氨酸作为多效性免疫调节剂克服透明细胞肾细胞癌中 TGF-β1/HIF 驱动的免疫逃逸——机制见解与转化治疗机会

Repurposing Seleno-L-Methionine as a Pleiotropic Immunomodulatory Agent to Overcome TGF-β1/HIF-Driven Immune Evasion in Clear Cell Renal Cell Carcinom

自相残杀效应降低的人源化 CD70 靶向 CAR-T 细胞对 AML 与 RCC 表现出强效抗肿瘤活性

Humanized CD70-targeted CAR-T cells with reduced fratricide demonstrate potent antitumor activity against AML and RCC.

实体瘤与血液系统恶性肿瘤中的肿瘤免疫治疗：进展、挑战与实践框架

Tumour immunotherapy in solid and hematologic malignancies: Progress, challenges, and a practical framework.

异体 CD70 靶向 CAR-T 细胞疗法治疗晚期肾细胞癌：I 期 TRAVERSE 试验结果

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial.

ALLO-316 在 CD70 阳性 ccRCC 中具有可管理的安全性和令人鼓舞的抗肿瘤活性。TRAVERSE 试验证明了异体 CAR-T 细胞疗法在实体瘤中作用的概念验证。

靶向 GPNMB 的 CAR-T 细胞治疗 MiT/TFE 家族融合驱动的实体瘤

GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.

用于透明细胞肾细胞癌的嵌合抗原受体免疫细胞疗法：最新进展与方向

Chimeric Antigen Receptor-Immune Cell-Based Therapies for Clear Cell Renal Cell Carcinoma: Latest Advancements and Directions.

CAR-T 细胞治疗在肾细胞癌中失败的原因

Why CAR T cell therapy fails in renal cell carcinoma.

重新思考晚期肾细胞癌：整合基因组学、免疫治疗与分子-正分子策略

Rethinking Advanced Renal Cell Carcinoma: Integrative Genomics, Immunotherapy, and Molecular-Orthomolecular Strategies.

泌尿系统肿瘤中的 NK 细胞与 CAR-NK 细胞治疗：进展、来自 CAR-T 的机制启示及未来方向

Natural killer and CAR-NK cell therapies in urological cancers: Progress, mechanistic lessons from CAR-T, and future directions.

透明细胞肾细胞癌的免疫治疗：现状、新策略与未来展望

Immunotherapy in clear cell renal cell carcinoma: current Status, novel Strategies, and future perspectives.